Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview
作者： Xiang-Lei He , Ming Zhao , Xiao-Dong Teng
DOI: 10.3978/J.ISSN.1000-9604.2016.02.05
关键词: Targeted therapy 、 Molecular pathogenesis 、 Molecular pathology 、 Cancer research 、 Medicine 、 Bladder cancer 、 Prognostics 、 Pathology
摘要: The knowledge of cellular mechanisms in malignances the bladder has grown exponentially. Molecular technologies have led to discovery molecular pathways distinguishing low-and high-grade urothelial neoplasms. This trend portends future which classification and diagnosis tumors through morphologic analysis will be supported by information correlating with prognosis targeted therapy. article outlines tumor pathology cancer an emphasis on several promising candidate biomarkers that may soon make their transition realm clinical management cancer.
amegroups.com参考文章(46)
Elena López-Knowles, Silvia Hernández, Núria Malats, Manolis Kogevinas, Josep Lloreta, Alfredo Carrato, Adonina Tardón, Consol Serra, Francisco X Real, EPICURO Study Group Investigators, PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Research. ,vol. 66, pp. 7401- 7404 ,(2006) , 10.1158/0008-5472.CAN-06-1182
Lucie C. Kompier, Irene Lurkin, Madelon N. M. van der Aa, Bas W. G. van Rhijn, Theo H. van der Kwast, Ellen C. Zwarthoff, FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy PLoS ONE. ,vol. 5, pp. e13821- ,(2010) , 10.1371/JOURNAL.PONE.0013821
Xue-Ru Wu, Urothelial tumorigenesis: a tale of divergent pathways Nature Reviews Cancer. ,vol. 5, pp. 713- 725 ,(2005) , 10.1038/NRC1697
Evanguelos Xylinas, Luis A. Kluth, Malte Rieken, Pierre I. Karakiewicz, Yair Lotan, Shahrokh F. Shariat, Urine markers for detection and surveillance of bladder cancer Urologic Oncology: Seminars and Original Investigations. ,vol. 32, pp. 222- 229 ,(2014) , 10.1016/J.UROLONC.2013.06.001
D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 74- 108 ,(2005) , 10.3322/CANJCLIN.55.2.74
Margaret A Knowles, Carolyn D Hurst, None, Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity Nature Reviews Cancer. ,vol. 15, pp. 25- 41 ,(2015) , 10.1038/NRC3817
Shahrokh F. Shariat, Daher C. Chade, Pierre I. Karakiewicz, Raheela Ashfaq, Hendrik Isbarn, Yves Fradet, Patrick J. Bastian, Matthew E. Nielsen, Umberto Capitanio, Claudio Jeldres, Francesco Montorsi, Seth P. Lerner, Arthur I. Sagalowsky, Richard J. Cote, Yair Lotan, Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer Journal of Urology. ,vol. 183, pp. 68- 75 ,(2010) , 10.1016/J.JURO.2009.08.115
A Petitjean, M I W Achatz, A L Borresen-Dale, P Hainaut, M Olivier, TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene. ,vol. 26, pp. 2157- 2165 ,(2007) , 10.1038/SJ.ONC.1210302
Nikhil Sapre, Praduymna Herle, Paul D. Anderson, Niall M. Corcoran, Christopher M. Hovens, Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder Pathology. ,vol. 46, pp. 274- 282 ,(2014) , 10.1097/PAT.0000000000000110
Sherri Z. Millis, David Bryant, Gargi Basu, Ryan Bender, Semir Vranic, Zoran Gatalica, Nicholas J. Vogelzang, Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clinical Genitourinary Cancer. ,vol. 13, ,(2015) , 10.1016/J.CLGC.2014.07.010